`Silvergate Pharmaceuticals, Name Change To
`Azurity Pharmaceuticals
`
`NEWS PROVIDED BY
`CutisPharma, Inc. =
`Jun 12, 2019, 06:00 ET
`
`WOBURN, Mass., June 12, 2019 /PRNewswire/ -- CutisPharma, Inc. announced today its acquisition of
`
`Silvergate Pharmaceuticals, Inc. and the unveiling of its new corporate brand for the unified company:
`
`Azurity Pharmaceuticals.
`
`"l am thrilled to announce the combination of two strong companies with a rich legacy meeting the needs
`of underserved patients, such as children and the elderly," said Neal I. Muni, MD, MSPH, Azurity
`Pharmaceuticals' Chief Executive Officer. "Azurity's mission, to make safe, high-quality treatments for
`patients requiring customized formulations for their care, is significantly bolstered by our combined
`
`resources and capabilities."
`
`NovaQuest Capital Management, LLC, the majority owner of Azurity Pharmaceuticals, supported
`CutisPharma and its management team in the transaction. Goldman Sachs Specialty Lending Group
`
`continues to support the company as a lender and arranged the debt financing for the transaction.
`
`Azurity's management team will be comprised of leaders from both the legacy CutisPharma and Silvergate
`teams. Azurity's Corporate Headquarters and Manufacturing Facility will be located in the Greater Boston
`area (Woburn, MA and Wilmington, MA, respectively); its R&D Campus will be located outside Kansas City,
`
`MO and the Corporate Satellite Campus will be located outside Denver, CO.
`
`g
`HELSINN EXHIBIT 2011
`
`Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.
`Page 1 of 3 IPR2025-00945
`
`
`
`
`
`
`
`
`Both companies have achieved several key milestones over the past year, including CutisPharma's FDA
`approval and launch of FIRVANQ® (vancomycin hydrochloride) for oral solution for the treatment of
`Clostridium difficile-associated diarrhea in early 2018, and Silvergate's submission of a New Drug
`Application (NDA) for its lead pipeline drug, SG-05, to the FDA, currently under review. Together as one
`company, Azurity will offer its valued customers a comprehensive portfolio across 12 products that serve
`
`multiple therapeutic areas.
`
`About Azurity Pharmaceuticals
`
`Azurity Pharmaceuticals is a privately-held specialty pharmaceutical company formed by the acquisition of
`Silvergate Pharmaceuticals, Inc. by CutisPharma, Inc., in May 2019. Azurity focuses on the needs of
`patients, especially children and the elderly, requiring customized, user-friendly drug formulations. Azurity's
`products, including Epaned” (enalapril maleate) Oral Solution, Qbrelis® (lisinopril) Oral Solution, Xatmep”
`(methotrexate) Oral Solution, FIRVANQ® (vancomycin hydrochloride) for oral solution, and FIRST® Unit-of-
`Use Compounding Kits have benefited millions of patients who are unable to swallow conventional oral
`dosage forms such as tablets and capsules and whose needs are not served by other commercially
`
`available therapies. For more information, visit www.azurity.com.
`
`SOURCE CutisPharma, Inc.
`
`Related Links
`
`http://www.cutispharma.com
`
`WANT YOUR COMPANY'S NEWS
`
`FEATURED ON PRNEWSWIRE.COM?
`
`GET STARTED
`
`Page 2 of 3
`
`
`
`
`
`
`
`
`440k+ 9k+ 270k+
`Newsrooms & Digital Media Journalists
`Influencers Outlets Opted In
`
`Page 3 of 3
`
`
`
`
`
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
